ArticleBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026
[Monitoring of HIV pre-exposure prophylaxis in Germany based on statutory health insurance claims data].
Article in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSince September 2019, HIV pre-exposure prophylaxis (PrEP) has been covered by statutory health insurance (SHI) in Germany. The objectives of the PrEP-Surv study module presented here were to monitor PrEP usage from 2019 to 2022 and to examine the feasibility of using SHI claims data for an annual monitoring of PrEP provision.
methodsPrEP users were identified and analyzed using anonymized BARMER data from 2019 to 2022. The analyses included determining the number of PrEP users each year; describing the cohorts by age, gender, and treatment adherence; identifying HIV infections; and calculating the rates of sexually transmitted infections or infectious diseases (STIs).
resultsThe number of PrEP users increased from 1058 in 2019 to 3194 in 2022. Demographic characteristics remained largely unchanged, while the average censored treatment adherence decreased from 98% in 2019 to 91% and 92% in the subsequent years. Two HIV infections were observed in two individuals, but the transmissions presumably occurred outside of PrEP use. No clear changes in STI rates were observed. DISCUSSION: The observed cohort appears to be comparable to other PrEP cohorts in Germany. The stability of the demographic characteristics possibly indicates that groups eligible for PrEP that were not reached at the beginning of PrEP reimbursement were subsequently also not reached. In addition to a description of PrEP care, a possible approach for the annual monitoring based on SHI claims data is presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.